Pfizer heart pill to be standalone therapy

Jul 26, 2006

U.S.-based Pfizer Inc., the world's largest pharmaceutical company, says it has decided to sell a new heart treatment medication as a standalone pill.

Pfizer initially announced it would sell the new drug, torcetrapib, only in combination with Lipitor, the company's best-selling cholesterol treatment medication, The New York Times reported. That decision produced strong opposition from physicians.

Torcetrapib, still being tested in clinical trials, is at least 18 months from receiving federal approval. But initial trial results indicate the drug substantially raises the levels of so-called good cholesterol -- a novel approach to preventing heart attacks and strokes, the Times said.

If Pfizer had offered torcetrapib only in a combination pill, that would have forced patients taking other cholesterol-lowering statins -- such as Merck & Co. Inc.'s Zocor -- to switch to Lipitor to obtain torcetrapib's benefits.

If proven effective, industry observers say the drug could potentially garner several billion dollars annually in sales.

Copyright 2006 by United Press International

Explore further: Modest effect of statins on diabetes risk and bodyweight related to mechanism of action

add to favorites email to friend print save as pdf

Related Stories

FDA adds heart warning to Pfizer anti-smoking pill

Jun 16, 2011

(AP) -- Federal health regulators are warning doctors and patients that Pfizer's anti-smoking drug Chantix may slightly increase the risk of heart attack and other cardiovascular problems.

Hormone-blocking drug reduces breast cancer risk

Jun 04, 2011

(AP) -- Millions of women at higher-than-usual risk of breast cancer have a new option for preventing the disease. Pfizer Inc.'s Aromasin cut the risk of developing breast cancer by more than half, without the side effects ...

UNICEF discloses vaccine prices for 1st time

May 29, 2011

UNICEF is for the first time publicizing what drugmakers charge it for vaccines, as the world's biggest buyer of lifesaving immunizations aims to spark price competition in the face of rising costs.

Recommended for you

Chikungunya fever identified in the United States

2 hours ago

(HealthDay)—Chikungunya fever is being seen in travelers returning to the United States from affected regions and should be considered as a diagnosis for febrile travelers, according to an ideas and opinions ...

Joint effort in standardizing due date estimation

2 hours ago

(HealthDay)—The American College of Obstetricians and Gynecologists, the American Institute of Ultrasound in Medicine, and the Society for Maternal-Fetal Medicine have jointly released new recommendations ...

Blood test for yeast infections approved

3 hours ago

(HealthDay)—The first blood test to detect five strains of yeast that cause rare blood infections in people with weakened immune systems has been approved by the U.S. Food and Drug Administration.

User comments : 0